PEOPLE - Changes at Gambro Holding:
This article was originally published in Clinica
Executive Summary
In light of healthcare group Gambro Holding's (Lund, Sweden) restructure into three independent companies (Gambro - renal products; Gambro Healthcare - renal care services; and Gambro BCT - cell therapy and blood products) under the holding entity of Indap AB, four executive leadership appointments have been announced. Peter Sjostrand is elected chairman of Gambro, succeeding Massimo Rossi, who has become chairman of Indap. And Thomas Glanzmann has been named CEO, succeeding Jan Bruneheim, who has become CEO of Indap.
You may also be interested in...
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.